cowen healthcare conference -...
TRANSCRIPT
1
Our purposeWe enable people with life-altering conditions to lead better lives
Cowen Healthcare Conference
Shire plcMarch 9, 2010
Michael ColaPresident, Specialty Pharmaceuticals
To be as brave as the people we help
2
THE “SAFE HARBOR” STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire’s results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of Shire’s Specialty Pharmaceutical and Human Genetic Therapies products, as well as the ability to secure and integrate new products for commercialization and/or development; government regulation of Shire’s products; Shire’s ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on Shire’s products; Shire’s ability to register, maintain and enforce patents and other intellectual property rights relating to its products; Shire’s ability to obtain and maintain government and other third-party reimbursement for its products; and other risks and uncertainties detailed from time to time in Shire’s filings with the Securities and Exchange Commission.
To be as brave as the people we help
3
Shire’s business model has been the key to our success
• Specialty biopharmaceutical company
• Treatment of symptomatic diseases
• Small sales forces
• Focus on lower risk projects with relatively fast development timelines and strong IP protection
15%169%EBITDA
16%190%Revenues
CAGR% Growth
Note: data covers timeframe of 1/1/2003 through 12/31/2009
Business Model Financial impact past 7 years (2003 – 2009)
To be as brave as the people we help
4
To be as brave as the people we help
4
Sustaining our financial performance
Focused on the needs of patients
Acquisitions and geographic expansion
Aspiration to grow sales in the mid-teens range year-on-year on average over the course of 2009 through 2015
Presence in 28 countries and growingAcquisition of EQUASYM facilitates immediate access to EU ADHD market
Pipeline opportunities for long term growth
Progress in development programs, antithrombotic, CarrierWave technology, HGT research, and new technology (Santaris)
Launching new products
INTUNIV – first and only selective a2A agonist indicated for the treatment of ADHD*
VPRIV (velaglucerase alfa) and REPLAGAL currently addressing unmet needs
Strategy is delivering
*The active ingredient in INTUNIV, is thought to selectively stimulate a2A adrenoreceptors in the prefrontal cortex. See Intuniv Wayne, PA: Shire US Inc; 08/2009 and Wang M, Ramos BP, Paspalas CD, et al. α2A-Adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex. Cell. 2007;129:397-410
To be as brave as the people we help
5
-$474m
2009 Total revenues in-line with 2008
VYVANSE
$3.0bn
XR Prod Sales
LIALDA
Other
ELAPRASE
2008 ACTUAL
2009ACTUAL
$3.0bn
XR Royalties
Core Products Reported GrowthFY +25%Q4 +36%
+$68m
+$186m
+$96m+$48m
+$37m
OtherFOSRENOL
REPLAGAL+$29m +$18m
To be as brave as the people we help
6
Core product sales growth
0
100
200
300
400
500
600
700
Q1 0 7 Q2 0 7 Q3 0 7 Q4 0 7 Q1 0 8 Q2 0 8 Q3 0 8 Q4 0 8 Q1 0 9 Q2 0 9 Q3 0 9 Q4 0 9
$mFY 2007$1.1bn
FY 2009$2.1bn
CAGR = 35%
Core product sales represent Shire’s product sales excluding ADDERALL XR.
To be as brave as the people we help
7
Specialty Pharma – 2009 key highlights
• Successfully managed through AXR generic erosion by capturing significant cash flow while growing VYVANSE sales
• Gained FDA approval for and launched INTUNIV
• Initiated multiple VYVANSE non-ADHD programs
• Acquired EQUASYM to jump-start EU ADHD footprint
• Approaching $0.5bn in net sales for the GI portfolio
• Expanded pipeline through multiple initiatives including the progression of multiple CarrierWave programs and SPD 535 (anagrelide analogue)
To be as brave as the people we help
8
VYVANSE demonstrated outstanding growth in 2009 in the face of ADDERALL XR going generic
Source: IMS NPA Monthly
13.3% (+2.6 share points)Dec Avg Market Share
+9.2%Total ADHD Market TRx Volume
+65%TRx Volume
+58%Net Sales
2009 vs. 2008Measure
• Q409 growth vs. Q408 growth was similarly strong• Market share grew in both the pediatric and adult patient segments
To be as brave as the people we help
9
To be as brave as the people we help
9
0
50,000
100,000
150,000
200,000
250,000
300,000
350,000
400,000
450,000
500,000
550,000
Jun-07
Aug-07Oct-
07Dec-0
7Feb
-08Apr-0
8Ju
n-08Aug-08Oct-
08Dec-0
8Feb
-09Apr-0
9Ju
n-09Aug-09Oct-
09Dec-0
9
TRx
Vol
ume
0%
2%
4%
6%
8%
10%
12%
14%
TRx
Shar
e
20+ TRx 0 - 19 TRx TRx Share
Vyvanse continues to grow share and volume
Adult launch
Vyvanse TRx Volume and Share June 2007 – January 2010
Source: IMS NPA Monthly
To be as brave as the people we help
10
3%
4%
5%
6%
7%
8%
9%
10%
11%
Jan-08
Feb-08
Mar-08
Apr-08
May-08
Jun-08Jul-0
8Aug
-08Sep
-08Oct-0
8Nov
-08Dec
-08Ja
n-09Feb
-09Mar-0
9Apr
-09May
-09Ju
n-09Ju
l-09
Aug-09
Sep-09
Oct-09
Nov-09
Dec-09
Jan-10
TRx S
hare
FDA Adult Approval
Adult Market Share
9.9%
• Adult launched one year after Pediatric
• Adult market growth is 4-5x Pediatric rate
+18.4%2009
+18.0%Q4
IMSGrowth YOY
Source: IMS NPA Monthly
VYVANSE Adult share continues to grow
To be as brave as the people we help
11
INTUNIV Launch update
• Although it is still early post launch for INTUNIV, we are very encouraged by the early indicators
• For the week ending February 26th, 2010, the overall national market share was 1.4%, and it is significantly higher in the important child / adolescent psychiatry and general psychiatry subsets of prescribers
• Approximately 7,500 physicians have prescribed INTUNIV
• Payors: formulary status still being reviewed by managed care plans. Currently most commercial managed care plans providing unrestricted access. Medicaid reimbursement progressing as expected
Source: IMS NPA
To be as brave as the people we help
12
0%
5%
10%
15%
20%
25%
30%
35%
Jul-0
7Aug
-07Sep
-07Oct-
07Nov-0
7Dec-0
7Ja
n-08
Feb-08
Mar-08
Apr-08
May-08
Jun-0
8Ju
l-08
Aug-08
Sep-08
Oct-08
Nov-08
Dec-08
Jan-0
9Feb
-09Mar-
09Apr-
09May
-09Ju
n-09
Jul-0
9Aug
-09Sep
-09Oct-
09Nov-0
9Dec-0
9Ja
n-10
TRx
Sha
re
PENTASA LIALDA GIBU Portfolio
Source: IMS NPA Monthly
Shire GI Portfolio Oral 5-ASA Monthly TRx Share
Shire GI Portfolio – Monthly TRx Share of Oral 5-ASA
Shire GI Portfolio TRx Share = 33.0%
To be as brave as the people we help
13
Select growth opportunities for Specialty Pharma portfolio
• INTUNIV: continuing progress on life cycle opportunities• On-going studies to evaluate efficacy in combination with stimulants and
evening dosing
• VYVANSE non-ADHD: Phase 2 clinical trials actively enrolling patients with data beginning in 2011• Adjunctive therapy in depression• Cognitive impairment in depression • Negative symptoms and cognitive impairment in schizophrenia
• Globalization of the ADHD portfolio• VYVANSE
• Launched in Canada this month• Market authorization filings under review in Mexico and Brazil• Continued enrollment of EU registration trials
• LIALDA: global Phase 3 trials in diverticulitis are ongoing
To be as brave as the people we help
14
Efforts continue to progress early pipeline products
• SPD 535 (anagrelide analogue) - platelet lowering ability without PDEIII inhibition • Initial PoC program targets prevention of thrombotic complications
associated with arteriovenous grafts in hemodialysis• Proof-of-principle for broader utility as an anti-coagulant• Estimated data availability – mid-2010
• CarrierWave• Primarily focused in pain and ADHD• Estimated data availability - mid-2010
To be as brave as the people we help
15
HGT Product launch preparations for 2010 and beyond
• VPRIV• Approved by FDA and launched in the US• Price at launch: $1350 for 400Uvial• Direct co-pay assistance to eligible patients in US to reduce
patient burden/access barrier• Continued financial assistance through patient associations• Over 400 patients have received VPRIV globally
• REPLAGAL • Focus on market growth and switch• Continue to address unmet need in the US • Fast track designation granted by FDA / rolling submission
initiated
To be as brave as the people we help
16
More than 300 cumulative patients added to REPLAGAL therapy in 2009 with the majority coming from patient switches
0
50
100
150
200
Q1 Q2 Q3 Q4
Net
new
pat
ient
add
ition
s
Net new treatment naïve patients Patient switches
To be as brave as the people we help
17
• Focused growth in R&D $• Leverage technology platforms• Incremental returns from investments• Sustained future growth
INVESTMENT INPIPELINE
• SG&A $ increases less than product sales over time• Sustained tax rate• Completion of manufacturing expansion
LEVERAGE INFRASTRUCTUREINVESTMENT
• Continued growth from existing portfolio• New product launches e.g. INTUNIV, VPRIV and REPLAGAL• Continued international growth
SUSTAINED CORE PRODUCT SALES GROWTH
KEY ELEMENTSGROWTH DYNAMICS
2010 Organic growth dynamics
To be as brave as the people we help
18
Potential launches from 2010-2016*
20122011 2013-2016
• VYVANSE (Canada)• FOSRENOL CKD
(EU)• VPRIV (US&EU)• FIRAZYR (ROW)• REPLAGAL (US)
• HGT 1110 (MLD)• IDURSULFASE-IT• SANFILIPPO ERT• HGT 2610 (GLD)• JUVISTA• LIALDA
DIVERTICULITIS• SPD 535
*Subject to regulatory approvals
• VYVANSE (EU)
2010
• VYVANSE (Latin America)
• FIRAZYR (US)• VPRIV (ROW)
To be as brave as the people we help
19
Solid foundation for future growth
• Strong financial performance• Core product sales* up 25% in 2009
• Proactive cost management
• Strong cash generation
• Strategy is delivering• Driving growth from balanced portfolio of 8 key products
• INTUNIV launch off to a strong start
• VPRIV approved by FDA and available pre-approval ex-US
• REPLAGAL received Fast Track designation
• Increasing our global reach
• Developing, advancing and enhancing our strong pipeline
• Aspiration to grow sales in the mid-teens range on average between 2009 and 2015
*Core products represent Shire’s products excluding ADDERALL XR
20
Our purposeWe enable people with life-altering conditions to lead better lives
Questions and Answers
21
Our purposeWe enable people with life-altering conditions to lead better lives
APPENDIX
To be as brave as the people we help
22
71%55%SG&A - Core product sales29%25%R&D - Core product sales
45%1,65325%2,067Core product sales
FINANCIAL RATIOS (% of core product sales)
34%33%EBITDA(2) (% total revenue)28%25%EBITDA(1) (% of product sales)
13%42%-3%42%SG&A 27%17%10%19%R&D
88%86%Gross margin27%2,754-2%2,694Product sales
y-o-yGrowthFY 08y-o-y
GrowthFY 09FINANCIAL RATIOS (% of product sales)
2009 Key financial ratios
(1) Excluding royalties and other revenues.(2) Including royalties and other revenues.This slide contains Non GAAP financial measures. See appendix for a list of items excluded from the US GAAP equivalent used to calculate these measures.
To be as brave as the people we help
23
Reported EPS-ADS
=Tax rate
• 5-10% growth in R&D and SG&A investment• Operating leverage on Core Product SalesR&D and SG&A
=Gross Margins
Growth in AXR royalty offset by lower other royalty incomeRoyalties
Core product growth > AXR declineTotal Product Sales
2009 growth continues, with potential to accelerateCore Product Sales
(see Appendix for more analysis)DirectionVersus FY 09
2010 Dynamics
Emerging shape of Shire 2010 Income Statement
Interest on convertible = $34m pa
Note:-0.08A 10 cent strengthening of the $ against the €0.03A 10 cent strengthening of the $ against the £
-0.05
EPS-ADS $Sensitivity to Forex Movements: